2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Decitabine, mBU/CY and ATG, mBU/CY - Stem Cell Transplant Complications, Relapse Leukemia | Phase 2 / Phase 3 | Unknown | Peking University People's Hospital | 55 | 2018-12-01 | 2019-05-29 |
Leukemia (2) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Leukemia, Myeloid (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (1) · Cytarabine (1) · Decitabine (1) · Homoharringtonine (1) · visilizumab (1)
Peking University People's Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (2)
Han Yue, Ph.D (1) · Xiao-Jun Huang (1)